DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "TIE-2 Receptor Agonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "TIE-2 receptor agonists - Pipeline Insight, 2021" report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in TIE-2 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence TIE-2 receptor agonists R&D. The therapies under development are focused on novel approaches for TIE-2 receptor agonists.
TIE-2 receptor agonists Emerging Drugs Chapters
This segment of the TIE-2 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIE-2 receptor agonists Emerging Drugs
AV-001: Vasomune Therapeutics
AV-001, a synthetic Angiopoietin 1 mimetic, activates the Tie2 receptor which is highly expressed on the surface of endothelial cells located within the vasculature.. AV-001 is designed to interact with the Tie2 receptor on a binding domain distinct from the natural ligands Angiopoietin 1 and Angiopoietin 2. Activation of Tie2 broadly promotes barrier defense against vascular leak and counteracts vascular inflammation by decreasing the activity of multiple pro-inflammatory factors.
AV-001 represents a novel multifactorial approach that acts at the cellular and tissue-level. This approach is in contrast to the traditional highly specific lock and key therapies aimed at killing the pathogen or individual targets within the inflammatory response pathway. There are no clinically available medications to treat vascular leak.
Razuprotafib: Aadi Biosciences
Razuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma.
Razuprotafib activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and we believe that it may be the most efficient pharmacologic approach to maintain normal Tie2 activation.
Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy. In addition, a subcutaneous formulation of razuprotafib is being explored for its therapeutic potential in treating or preventing ARDS associated with COVID-19.
TIE-2 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different TIE-2 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on TIE-2 receptor agonists
There are approx. 4+ key companies which are developing the TIE-2 receptor agonists. The companies which have their TIE-2 receptor agonists drug candidates in the most advanced stage, i.e. Phase II include, Aadi Biosciences.
TIE-2 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIE-2 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIE-2 receptor agonists drugs.
Key Questions Answered
How many companies are developing TIE-2 receptor agonists drugs?
How many TIE-2 receptor agonists drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIE-2 receptor agonists?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TIE-2 receptor agonists therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for TIE-2 receptor agonists and their status?
What are the key designations that have been granted to the emerging drugs?
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/llf1sq
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005527/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900